Literature DB >> 11843289

Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias.

John Meletis1, Evangelos Terpos, Michalis Samarkos, Christos Meletis, Effie Apostolidou, Veroniki Komninaka, Konstantinos Korovesis, Konstantinos Anargyrou, Olga Benopoulou, Despina Mavrogianni, Eleni Variami, Nora Viniou, Konstantinos Konstantopoulos.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by a decrease or absence of glycosylphosphatidylinositol (GPI)-anchored molecules such as CD55 and CD59 from the surface of affected cells, resulting in intravascular hemolysis, cytopenia, and venous thrombosis. A PNH-like phenotype has been detected in various hematological disorders, mainly in aplastic anemia and myelodysplastic syndromes, but also in lymphoproliferative syndromes (LPSs). To the best of our knowledge, CD55- or CD59-deficient red cells have not been detected in plasma cell dyscrasias (PCDs). The aim of this study was the detection of CD55- and/or CD59-deficient red cell populations in patients with PCD. Seventy-seven patients were evaluated; 62 with multiple myeloma (MM), 7 with Waldenstrom macroglobulinemia (WM), 6 with monoclonal gammopathy of undetermined significance (MGUS), and 2 with heavy chain disease (HCD). The sephacryl gel microtyping system was applied; Ham and sucrose lysis tests were also performed on all samples with CD55- or CD59-negative populations. Red cells deficient in both molecules were detected in 10 (12.9%) of 77 patients with PCD: 2 (28.6%) of 7 with WM, 1 (16.6%) of 6 with MGUS, 6 (9.6%) of 62 with MM, and 1 of 2 patients with HCD. Isolated CD55 deficiency was found in 28.5% of all PCD patients, whereas isolated CD59 deficiency was not observed in any patients. These findings illustrate the existence of the PNH phenotype in the red cells of patients with PCD; further investigation is needed into the mechanisms and significance of this phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11843289     DOI: 10.1007/bf02981977

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

1.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin's lymphoma.

Authors:  H Fukuda; T Seya; T Hara; M Matsumoto; T Kinoshita; T Masaoka
Journal:  Immunol Lett       Date:  1991-08       Impact factor: 3.685

3.  Detection of "PNH red cell" populations in hematological disorders using the Sephacryl Gel Test micro typing system.

Authors:  J Meletis; E Michali; M Samarkos; K Konstantopoulos; C Meletis; E Terpos; A Tsimberidou; E Chandrinou; N Viniou; Y Rombos; G A Pangalis; X Yataganas; D Loukopoulos
Journal:  Leuk Lymphoma       Date:  1997-12

Review 4.  The molecular basis of paroxysmal nocturnal hemoglobinuria.

Authors:  V Rosti
Journal:  Haematologica       Date:  2000-01       Impact factor: 9.941

5.  Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.

Authors:  V C Taylor; M Sims; S Brett; M C Field
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

6.  Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.

Authors:  D E Dunn; P Tanawattanacharoen; P Boccuni; S Nagakura; S W Green; M R Kirby; M S Kumar; S Rosenfeld; N S Young
Journal:  Ann Intern Med       Date:  1999-09-21       Impact factor: 25.391

7.  Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.

Authors:  J Meletis; E Terpos; M Samarkos; C Meletis; E Apostolidou; V Komninaka; K Korovesis; D Mavrogianni; D Boutsis; E Variami; N Viniou; K Konstantopoulos; D Loukopoulos
Journal:  Hematol J       Date:  2001

8.  A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglobinuria: detection of DAF(CD55)- and HRF20(CD59)- erythrocytes in microtyping cards.

Authors:  B Nilsson; U Hagström; A Englund; J Säfwenberg
Journal:  Vox Sang       Date:  1993       Impact factor: 2.144

9.  Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link.

Authors:  A Griscelli-Bennaceur; E Gluckman; M L Scrobohaci; P Jonveaux; T Vu; A Bazarbachi; E D Carosella; F Sigaux; G Socié
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

10.  Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.

Authors:  B Hertenstein; B Wagner; D Bunjes; C Duncker; A Raghavachar; R Arnold; H Heimpel; H Schrezenmeier
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

View more
  6 in total

Review 1.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

2.  A paroxysmal nocturnal haemoglobinuria progress with waldenström macroglobulinemia along with T cell monoclonal expansion.

Authors:  Hongying Liu; Chuan He; Huanling Zhu; Xianglong Li; Chunli Yang; Dewan Zhao; Xiujin Wu
Journal:  Indian J Hematol Blood Transfus       Date:  2014-01-24       Impact factor: 0.900

Review 3.  Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure.

Authors:  Shinji Nakao; Chiharu Sugimori; Hirohito Yamazaki
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

4.  Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma.

Authors:  Evangelos Terpos; Michalis Samarkos; Christos Meletis; Effie Apostolidou; Maria Tsironi; Konstantinos Korovesis; Despina Mavrogianni; Nora Viniou; John Meletis
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

5.  The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon.

Authors:  John V Asimakopoulos; Evangelos Terpos; Loula Papageorgiou; Olga Kampouropoulou; Dimitris Christoulas; Anastasios Giakoumis; Michael Samarkos; George Vaiopoulos; Konstantinos Konstantopoulos; Maria K Angelopoulou; Theodoros P Vassilakopoulos; John Meletis
Journal:  Med Sci Monit       Date:  2014-01-27

Review 6.  The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease.

Authors:  Christopher B Toomey; David M Cauvi; Kenneth M Pollard
Journal:  Autoimmune Dis       Date:  2014-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.